Pascual Balsalobre
About Pascual Balsalobre
Pascual Balsalobre is a Cell Therapy Account Manager at Kite Pharma, where he has worked since 2019. He has co-authored over 40 papers on hematologic cancer and has extensive experience in clinical research and education.
Work at Kite Pharma
Pascual Balsalobre has been serving as a Cell Therapy Account Manager at Kite Pharma since 2019. In this role, he is responsible for managing accounts related to cell therapy, particularly focusing on the application of CAR-T therapies in hematologic cancers. His experience in the field contributes to the company's mission of advancing innovative therapies for patients with cancer.
Education and Expertise
Pascual Balsalobre earned a Doctor of Philosophy (PhD) in Epidemiología y Salud Pública from Universidad Autónoma de Madrid in 2015. He also holds a Máster Ciencias de la Salud from Universidad de Alicante, completed in 2010. His educational background includes a Bachelor's degree in Registered Nursing from Hogeschool Zeeland, which he obtained in 2004. This diverse educational foundation supports his expertise in hematologic cancer and cell therapy.
Background in Hematology and Transplantation
Balsalobre has extensive experience in the field of hematology and transplantation. He completed a fellowship in hematopoietic transplant clinical research at the European Society for Blood and Marrow Transplantation Registry in 2006. Prior to his current role, he worked as a Stem Cell Transplant Coordinator at Comunidad de Madrid from 2007 to 2012, where he managed transplant processes and patient care.
Research Contributions and Publications
Pascual Balsalobre has co-authored over 40 papers focusing on the genetic and clinical aspects of hematologic cancer. His research contributions reflect his commitment to advancing knowledge in the field. He has also collaborated with national and international scientific societies, including GETH and EBMT, enhancing the understanding of hematopoietic transplantation.
Achievements in Clinical Trials and Education
Balsalobre played a key role in the market launch of Yescarta, a pioneering anti-CD19 CAR-T therapy for patients with relapse/refractory lymphoma. He has regular teaching experience at the university level and in scientific workshops, sharing his knowledge and expertise with future professionals in the field of hematology and cell therapy.